Replimune Group, Inc. has made headlines following the recent stock transactions reported by its director, Kapil Dhingra. The filing reveals that Dhingra exercised stock options and sold shares, which could signal confidence in the company's future and a strategic approach to managing tax obligations.

Background

Replimune Group, Inc. operates in the biological products sector, specifically focusing on products that do not include diagnostic substances. The company is listed on the Nasdaq under the ticker symbol REPL and is classified under the SIC code 2836. Recent filings include a Form 4 submitted on November 3, 2026, detailing the transactions made by Dhingra.

What the Filing Says

The SEC filing indicates that on November 2, 2026, Dhingra exercised a non-qualified stock option for 43,169 shares at a price of $1.75 per share. Additionally, he sold 21,500 shares at a weighted average price of $19.00 to cover tax withholding obligations related to the stock option exercise. The filing notes that the shares were sold in multiple transactions at prices ranging from $18.99 to $19.03.

Impact

This update may affect Replimune's investors and stakeholders, as it reflects the company's ongoing activities and the actions of its leadership. The transactions also highlight the importance of managing tax obligations for executives in the industry. Competitors in the biological products sector will likely monitor these developments closely.

What's Next

The filing does not say what happens next.